Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

171P - Pharmacodynamic (PD) biomarker analysis from CheckMate (CM) 8KX: a multitumor study of a subcutaneous (SC) formulation of nivolumab (NIVO) monotherapy

Date

08 Dec 2022

Session

Poster Display

Presenters

Iwona Lugowska

Citation

Annals of Oncology (2022) 16 (suppl_1): 100104-100104. 10.1016/iotech/iotech100104

Authors

I. Lugowska1, C.G.C.A. Jackson2, D. Perumal3, A. O’donnell4, R.T. North5, P.A. Calvo Ferrandiz6, L.M. Latten-Jansen7, C.G. Sánchez8, L.M. Medina Rodríguez9, A. Santoro10, L. Li3, K. Sidik3, T. Tang3, J.S. Deutsch11, J. Taube12, C. Horak3, S. Ravimohan3, S. Lonardi13

Author affiliations

  • 1 Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw/PL
  • 2 Dunedin Hospital, Dunedin/NZ
  • 3 Bristol Myers Squibb, Princeton/US
  • 4 Capital and Coast Health, Wellington/NZ
  • 5 Tauranga Hospital, Tauranga/NZ
  • 6 Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 7 Maastricht University Medical Center (MUMC), Maastricht/NL
  • 8 Pontificia Universidad Católica de Chile, Santiago/CL
  • 9 Hospital Universitario Virgen de la Victoria, Málaga/ES
  • 10 Istituto Clinico Humanitas, Rozzano/IT
  • 11 Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore/US
  • 12 Johns Hopkins Sidney Kimmel Cancer Center, Baltimore/US
  • 13 IOV - Istituto Oncologico Veneto IRCCS, Padova/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 171P

Background

CM 8KX is a phase 1/2 study of an SC NIVO formulation with a permeation enhancer, recombinant human hyaluronidase PH20 enzyme (rHuPH20), developed to allow rapid delivery and reduced treatment burden compared with intravenous (IV) NIVO administration. We report PD biomarker changes in the tumor microenvironment and peripheral blood from CM 8KX and key PD biomarker comparisons between SC and IV NIVO.

Methods

Patients were checkpoint inhibitor–naive, ≥ 18 years of age, ECOG performance status 0–1, with metastatic/unresectable solid tumors and measurable disease. Patients received SC NIVO 720 mg ± rHuPH20, SC NIVO 960 mg ± rHuPH20, or SC NIVO 1200 mg + rHuPH20. Paired baseline and on-treatment tumor biopsies were assessed for CD8+ tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 expression on tumor cells (TC PD-L1) by immunohistochemistry. Soluble PD-1 (sPD-1), interferon gamma (IFNγ), CXCL9, and CXCL10 were assessed in serum from cycle (C) 1 day (D) 1 to C2D1. sPD-1 changes were compared with unpublished data from IV NIVO 3 mg/kg Q2W administration in CM 038; other biomarkers were compared with published data.

Results

As previously reported, SC NIVO ± rHuPH20 resulted in numerical mean increases from baseline to C1D15 in CD8+ TILs (5.0% [95% CI, −17.5 to 27.5]) and TC PD-L1 (2.8% [95% CI, −12.8 to 18.4]), which are surrogates for tumoral IFNγ activity. These observations were consistent with those published for IV NIVO in several indications. sPD-1 increased significantly following SC NIVO across dose cohorts, similar to increases observed in CM 038. Early increases in IFNγ and CXCL9 were observed following SC NIVO ± rHuPH20, with significant cycle-day effects but no apparent dose dependence. Numerical increases in CXCL10 were also observed. These increases are consistent with published IV NIVO data from CM 038.

Conclusions

Increases in tumor biomarkers and changes in key peripheral PD markers demonstrate immune activation post-SC NIVO. Despite the limitations of cross-trial comparisons, PD effects are consistent with historical IV NIVO data from CM 038. The results support further evaluation of SC NIVO + rHuPH20 in phase 3 studies.

Clinical trial identification

NCT03656718 and NCT01621490.

Editorial acknowledgement

Editorial support was provided by Sandra Page, PhD, of Spark Medica Inc.

Legal entity responsible for the study

Bristol Myers Squibb.

Funding

Bristol Myers Squibb.

Disclosure

C.G.C.A. Jackson: Non-Financial Interests, Personal, Advisory Role: Merck Sharp & Dohme; Financial Interests, Institutional, Funding: Athenex. D. Perumal: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. I. Lugowska: Financial Interests, Personal, Funding: Roche, MSD, AstraZeneca, Boehringer Ingelheim, Janssen, Pfizer, Amgen, Incyte, Macrogenics, RyVu, Rhizen, Agenus. A. O’Donnell: Other, Institutional, Full or part-time Employment: Capital and Coast Health, Bowen Icon Cancer Centre. R.T. North: Non-Financial Interests, Institutional, Principal Investigator: BOP Clinical Trials Unit. P.A. Calvo Ferrandiz: Non-Financial Interests, Personal, Full or part-time Employment: Hospital Universitario Gregorio Marañón. L.M. Latten-Jansen: Non-Financial Interests, Personal and Institutional, Principal Investigator: Maastricht University Medical Center+. A. Santoro: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Servier, Gilead, Pfizer, Eisai, Bayer, Merck Sharp & Dohme, Incyte; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Speaker’s Bureau: Takeda, Bristol Myers Squibb, Roche, AbbVie , Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, Lilly, Sandoz, Eisai, Novartis, Bayer, Merck Sharp & Dohme. L. Li: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb. K. Sidik: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. T. Tang: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. J.S. Deutsch: Financial Interests, Personal, Other, Application No: 63/313,548: Patent pending. J. Taube: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Merck Sharpe & Dohme, AstraZeneca, Replimune; Financial Interests, Personal, Research Grant: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Stocks/Shares: Akoya Biosciences; Financial Interests, Personal and Institutional, Advisory Board: Akoya Biosciences; Financial Interests, Personal and Institutional, Research Grant: Akoya Biosciences; Non-Financial Interests, Institutional, Other, Equipment loan: Akoya Biosciences; Non-Financial Interests, Institutional, Other, Reagent provision: Akoya Biosciences. C. Horak: Financial Interests, Personal, Full or part-time Employment: Palleon Pharmaceuticals; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. S. Ravimohan: Financial Interests, Institutional, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. S. Lonardi: Financial Interests, Personal, Advisory Board: Amgen, Merck Serono, Lilly, Servier, AstraZeneca, MSD, Incyte, Daiichi Sankyo, Bristol Myers Squibb, Mirati; Financial Interests, Personal, Invited Speaker: Pierre-Fabre, GlaxoSmithKline, Roche; Financial Interests, Institutional, Invited Speaker: Amgen, Merck Serono, Bayer, Roche, Lilly, AstraZeneca, Bristol Myers Squibb. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.